Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...

In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.

US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...

FDA approval of IMULDOSA was granted based on a comprehensive clinical development program. The data showed that IMULDOSA is similar to its reference product STELARA in terms of pharmacokinetic ...

UCB SA (OTCMKTS:UCBJF – Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 419,400 ...

Machine learning models may be a useful tool for psoriasis severity assessment in clinical settings, despite a need for further research.

Patients with rheumatoid arthritis (RA) undergoing standard-of-care treatment frequently have persisting pain.

Arthritis in your 20s might seem unusual, but it's becoming more frequent. Check out these 7 warning signs and symptoms of ...

Persistent pain is common in rheumatoid arthritis. But patient-reported outcomes tools can help clinicians determine a care plan.